Effectiveness of the Japanese DOLOPLUS-2: a pain assessment scale for patients with moderate-to-severe dementia

被引:6
|
作者
Ando, Chiaki [1 ]
Ito, Yoshinori [2 ]
Amemiya, Shimon [2 ]
Tamura, Kyoko [2 ]
Kako, Ken [2 ]
Tsuzura, Satoko [2 ]
Yoshida, Ryoichi [2 ]
Hishinuma, Michiko [3 ]
机构
[1] Bunkyo Gakuin Univ, Dept Nursing Sci, Fac Hlth Sci Technol, Tokyo, Japan
[2] Yokufukai Geriatr Hosp, Dept Neurol, Tokyo, Japan
[3] St Lukes Int Univ, Dept Nursing Sci, Tokyo, Japan
关键词
moderate-to-severe dementia; observational instrument; pain assessment; ALZHEIMERS-DISEASE; OLDER-ADULTS; MANAGEMENT; STATE;
D O I
10.1111/psyg.12168
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
BackgroundThis study aimed to assess whether the Japanese DOLOPLUS-2 scale could effectively identify pain in elderly individuals with moderate-to-severe dementia. MethodsThis study used a pre-test/post-test design with purposive sampling to select an experimental group and a historical control group. The inclusion criteria were a Functional Assessment Staging score of 5 or 6, a diagnosis of an orthopaedic disease that typically involves pain, the ability to say I am currently in pain' (to prevent medication errors), and a total DOLOPLUS-2 scale score 5 at the first pain assessment. In the experimental group (n = 19), each patient was assessed by the DOLOPLUS-2 scale at 2PM and 9PM each day for 5 days. If a patient's total score was 5, analgesics were prescribed and the patient was re-assessed approximately 3 hours later. In the control group (n = 20), data were collected from medical records over a 1-year period, and we matched the characteristics of the control group to that of the experimental group. We also reviewed nursing records to determine the number of times analgesics had been administered over the 5 days after the nurses had first recorded that the patient had experienced pain. ResultsAmong the 19 patients in the experimental group, 15 received pain medication because of a total pain score 5. Before treatment, their mean DOLOPLUS-2 scale score was 7.5 3.2, and their score significantly decreased to 2.9 +/- 2.1 (P < 0.001) after treatment. The experimental group also received significantly more treatments with analgesic medication than the control group ((2) = 16.033, P < 0.001, phi = 0.641). ConclusionThis study's findings suggested that the Japanese DOLOPLUS-2 scale could adequately identify pain in elderly individuals with moderate-to-severe dementia.
引用
收藏
页码:315 / 322
页数:8
相关论文
共 50 条
  • [21] The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-to-severe pain
    Kang, Jung Hun
    Oh, Sung Yong
    Song, Seo-Young
    Lee, Hui-Young
    Kim, Jung Han
    Lee, Kyoung Eun
    Lee, Hye Ran
    Hwang, In Gyu
    Park, Se Hoon
    Kim, Won Seok
    Park, Young Suk
    Park, Keunchil
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2015, 30 (01) : 88 - 95
  • [22] Lebrikizumab Combined with Topical Corticosteroids Improves Patient- reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis
    Tanaka, Akio
    Igawa, Ken
    Takahashi, Hidetoshi
    Shimizu, Ryosuke
    Kataoka, Yoko
    Torisu-Itakura, Hitoe
    Morisaki, Yoji
    Montmayeur, Sonia
    Katoh, Norito
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [23] Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma
    Hanania, Nicola A.
    Niven, Robert
    Chanez, Pascal
    Antoine, Deschildre
    Pfister, Pascal
    Conde, Lorena Garcia
    Jaumont, Xavier
    WORLD ALLERGY ORGANIZATION JOURNAL, 2022, 15 (10):
  • [24] Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
    Gooderham, Melinda
    Papp, Kim A.
    Lynde, Charles
    Delorme, Isabelle
    Beecker, Jennifer
    Albrecht, Lorne
    Dei-Cas, Ignacio
    Brassard, Danielle
    Prajapati, Vimal H.
    Vieira, Antonio
    Rihakova, Lenka
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 535 - 553
  • [25] Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease
    Coluzzi, Flaminia
    Raffa, Robert B.
    Pergolizzi, Joseph
    Rocco, Alessandra
    Locarini, Pamela
    Cenfra, Natalia
    Cimino, Giuseppe
    Mattia, Consalvo
    JOURNAL OF PAIN RESEARCH, 2015, 8 : 229 - 238
  • [26] Low-dose methoxyflurane analgesia in adolescent patients with moderate-to-severe trauma pain: a subgroup analysis of the STOP! study
    Hartshorn, Stuart
    Dissmann, Patrick
    Coffey, Frank
    Lomax, Mark
    JOURNAL OF PAIN RESEARCH, 2019, 12 : 689 - 700
  • [27] Assessment of an automated neural network based on unsupervised oximetry at home in the diagnosis of patients with moderate-to-severe SAHS and COPD
    Sedano, Andrea Crespo
    Blanco, Ana Maria Andres
    Gonzalez, Daniel Alvarez
    Gutierrez-Tobal, Gonzalo Cesar
    Domingo, Carmen Ainhoa Arroyo
    Arribas, Julio De Frutos
    Albi, Tomas Ruiz
    Garcia, Laura Juez
    Sanchez, Roberto Hornero
    Matias, Felix Del Campo
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [28] Spanish adaptation and validation of the Pain Assessment Scale in Advanced Dementia (PAINAD) in patients with dementia and impaired verbal communication: cross-sectional study
    Canton-Habas, Vanesa
    Del Pilar Carrera-Gonzalez, Maria
    Teresa Moreno-Casbas, Maria
    Rich-Ruiz, Manuel
    BMJ OPEN, 2021, 11 (06):
  • [29] Determination of moderate-to-severe postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods
    Gerbershagen, H. J.
    Rothaug, J.
    Kalkman, C. J.
    Meissner, W.
    BRITISH JOURNAL OF ANAESTHESIA, 2011, 107 (04) : 619 - 626
  • [30] Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: A multicentre cohort study
    Okabayashi, Shinji
    Yamazaki, Hajime
    Tominaga, Keiichi
    Miura, Miki
    Sagami, Shintaro
    Matsuoka, Katsuyoshi
    Yamaguchi, Yoshiharu
    Noake, Toshihiro
    Ozeki, Keiji
    Miyazaki, Ryosuke
    Kamano, Toshiaki
    Fukuda, Tomohiro
    Yoshioka, Kyoko
    Ando, Katsuyoshi
    Fukuzawa, Masakatsu
    Andoh, Akira
    Yamamoto, Yosuke
    Hibi, Toshifumi
    Kobayashi, Taku
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (12) : 1569 - 1580